The stock of Ionis Pharmaceuticals Inc (IONS) has gone down by -1.47% for the week, with a -12.83% drop in the past month and a -12.98% drop in the past quarter. The volatility ratio for the week is 2.98%, and the volatility levels for the past 30 days are 3.66% for IONS. The simple moving average for the past 20 days is -9.15% for IONS’s stock, with a -10.24% simple moving average for the past 200 days.
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
Moreover, the 36-month beta value for IONS is 0.39. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IONS is 144.60M and currently, short sellers hold a 7.03% of that float. On September 24, 2024, IONS’s average trading volume was 1.64M shares.
IONS) stock’s latest price update
The stock of Ionis Pharmaceuticals Inc (NASDAQ: IONS) has decreased by -2.22 when compared to last closing price of 41.83. Despite this, the company has experienced a -1.47% fall in its stock price over the last five trading sessions. zacks.com reported 2024-09-11 that IONS’ shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with BMO Capital Markets repeating the rating for IONS by listing it as a “Market Perform.” The predicted price for IONS in the upcoming period, according to BMO Capital Markets is $60 based on the research report published on August 02, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $53. The rating they have provided for IONS stocks is “Outperform” according to the report published on July 24th, 2024.
Jefferies gave a rating of “Buy” to IONS, setting the target price at $75 in the report published on July 16th of the current year.
IONS Trading at -13.07% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.88% of loss for the given period.
Volatility was left at 3.66%, however, over the last 30 days, the volatility rate increased by 2.98%, as shares sank -11.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.16% lower at present.
During the last 5 trading sessions, IONS fell by -0.48%, which changed the moving average for the period of 200-days by -17.28% in comparison to the 20-day moving average, which settled at $44.74. In addition, Ionis Pharmaceuticals Inc saw -19.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Geary Richard S, who sale 331 shares at the price of $49.63 back on Aug 29 ’24. After this action, Geary Richard S now owns 84,823 shares of Ionis Pharmaceuticals Inc, valued at $16,428 using the latest closing price.
Geary Richard S, the EVP, Chief Development Officer of Ionis Pharmaceuticals Inc, sale 320 shares at $49.16 during a trade that took place back on Aug 28 ’24, which means that Geary Richard S is holding 85,154 shares at $15,731 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.45 for the present operating margin
- 0.97 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.45. The total capital return value is set at -0.15. Equity return is now at value -105.63, with -12.91 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.19. The debt to equity ratio resting at 6.87. The interest coverage ratio of the stock is -4.44.
Currently, EBITDA for the company is -322.84 million with net debt to EBITDA at -5.11. When we switch over and look at the enterprise to sales, we see a ratio of 10.04. The receivables turnover for the company is 29.83for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.
Conclusion
To wrap up, the performance of Ionis Pharmaceuticals Inc (IONS) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
